• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Oren Liora

    3/18/26 7:00:27 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NCEL alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Oren Liora

    (Last)(First)(Middle)
    C/O NEWCELX LTD.
    THE CIRCLE 6

    (Street)
    ZURICH8058

    (City)(State)(Zip)

    SWITZERLAND

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/18/2026
    3. Issuer Name and Ticker or Trading Symbol
    NewcelX Ltd. [ NCEL ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Option to Purchase Ordinary Shares (1)11/04/2035Ordinary Shares9,117(2)$7.62D
    Explanation of Responses:
    1. As of the date of this Form 3, options to purchase 759 ordinary shares are vested and currently exercisable. The remaining options vest and become exercisable beginning on May 4, 2026 in 11 equal installments on a quarterly basis, subject to the Reporting Person's continued service.
    2. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the NewcelX Ltd. Share Option Plan Regulation 2021 must be registered in the name of a trustee.
    /s/ Liora Oren03/18/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $NCEL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NCEL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NCEL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Samuel Olivier bought $225,000 worth of shares (81,818 units at $2.75) (SEC Form 4)

    4 - NewcelX Ltd. (0001783036) (Issuer)

    4/29/26 4:05:32 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CSO and Director Revel Michel bought $149,999 worth of shares (54,545 units at $2.75), increasing direct ownership by 6% to 957,530 units (SEC Form 4)

    4 - NewcelX Ltd. (0001783036) (Issuer)

    4/29/26 4:05:15 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by NewcelX Ltd.

    3 - NewcelX Ltd. (0001783036) (Issuer)

    3/18/26 7:04:27 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

    Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi

    5/27/26 7:55:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

    NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan

    4/30/26 8:15:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

    ZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (NASDAQ:ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy. The updated presentation outlines the integration of NewcelX's scalable stem-cell-derived islet replacement platform with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart, a targ

    4/20/26 7:37:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    SEC Filings

    View All

    $NCEL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 6-K filed by NewcelX Ltd.

    6-K - NewcelX Ltd. (0001783036) (Filer)

    5/27/26 8:00:16 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form EFFECT filed by NewcelX Ltd.

    EFFECT - NewcelX Ltd. (0001783036) (Filer)

    5/18/26 12:15:18 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form D filed by NewcelX Ltd.

    D - NewcelX Ltd. (0001783036) (Filer)

    5/12/26 9:51:11 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Samuel Olivier bought $225,000 worth of shares (81,818 units at $2.75) (SEC Form 4)

    4 - NewcelX Ltd. (0001783036) (Issuer)

    4/29/26 4:05:32 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CSO and Director Revel Michel bought $149,999 worth of shares (54,545 units at $2.75), increasing direct ownership by 6% to 957,530 units (SEC Form 4)

    4 - NewcelX Ltd. (0001783036) (Issuer)

    4/29/26 4:05:15 PM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Financials

    Live finance-specific insights

    View All

    NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

    NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan

    4/30/26 8:15:00 AM ET
    $ELDN
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NCEL
    Leadership Updates

    Live Leadership Updates

    View All

    NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

    ZURICH and NESS ZIONA, Israel, Jan. 5, 2026 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX"), a biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Dr. Julien Boisdron, MD, a seasoned diabetes expert with extensive experience in Swiss big pharma leadership to its Scientific Advisory Board ("SAB"). Dr. Boisdron brings more than two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a major Swiss-based multinational large cap ph

    1/5/26 7:00:00 AM ET
    $NCEL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

    ZURICH and NESS ZIONA, Israel, Nov. 17, 2025 /PRNewswire/ -- NewcelX Ltd. (NASDAQ:NCEL) ("NewcelX" or "the Company"), a clinical-stage biotechnology company developing cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, today announced the appointment of Prof. Jeremy Shefner, MD, PhD, to the Company's Scientific Advisory Board ("SAB").   Prof. Shefner is a highly respected neurologist specializing in amyotrophic lateral sclerosis (ALS) and neuromuscular disorders. He serves as Professor of Neurology and Chief Medical Officer for Clinical Research at Barrow Neurological Institute in Phoenix, Arizona — an internationally recognized leader in the treatment and

    11/17/25 7:00:00 AM ET
    $NCEL
    $NLSP
    Biotechnology: Pharmaceutical Preparations
    Health Care